Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 2/20 | 0.84 |
| ▸ | MAOB | P27338 | 2/20 | 0.84 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.82 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.82 |
| ▸ | DPP4 | P27487 | 1/20 | 0.82 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.82 |
| ▸ | RELA | Q04206 | 1/20 | 0.82 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.82 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flavokawain B SCHEMBL1938260 | 1.00 | MAPT (1.00) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL30382640 | 1.00 | MAPT (1.00) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL25185055 | 1.00 | MAPT (1.00) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL29439356 | 1.00 | MAPT (1.00) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL30384635 | 0.99 | MAPT (0.97) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL25265211 | 0.99 | MAPT (0.97) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL25193713 | 0.99 | MAPT (0.97) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL25278514 | 0.94 | MAPT (0.88) | MAPTKMT2ACYP3A4TP53ATM | |
| Flavokawain B SCHEMBL25190550 | 0.93 | MAPT (0.86) | MAPTKMT2ACYP3A4TP53ATM | |
| SCHEMBL25192230 | 0.92 | MAPT (0.86) | MAPTKMT2ACYP3A4TP53ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213637-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2025-07-03 | — | — | US | claimed |
| US-20240050509-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2024-02-15 | — | — | US | claimed |
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| EP-4036583-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board of Regents, The University of Texas System (US) | 2022-08-03 | — | — | EP | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| US-11154527-B2 | Dermatophytosis prophylaxis and treatment | THE CHILDREN'S MERCY HOSPITAL (US) | 2021-10-26 | — | — | US | claimed |
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2021-07-29 | — | — | US | claimed |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KUALITY HERBCEUTICS LLC (US) | 2021-02-16 | — | — | US | claimed |
| US-20200261529-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2020-08-20 | — | — | US | claimed |
| US-20200197407-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-06-25 | — | — | US | claimed |
| EP-3665482-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board Of Regents, The University Of Texas System (US) | 2020-06-17 | — | — | EP | claimed |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | Kuality Herbceutics, LLC (US) | 2020-04-21 | — | — | US | claimed |
| US-10406132-B2 | Dermatophytosis prophylaxis and treatment | THE CHILDREN'S MERCY HOSPITAL (US) | 2019-09-10 | — | — | US | claimed |
| WO-2019040828-A1 | KAVA EXTRACTS, ISOLATED KAVALACTONES, AND USES IN TREATING TOBACCO AND NICOTINE ADDICTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-02-28 | — | — | WO | claimed |
| WO-2019033041-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-02-14 | — | — | WO | claimed |
| US-20180104210-A1 | DERMATOPHYTOSIS PROPHYLAXIS AND TREATMENT | THE CHILDREN'S MERCY HOSPITAL | 2018-04-19 | — | — | US | claimed |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2016-09-29 | — | — | US | claimed |
| EP-3068416-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Kuality Herbceutics LLC (US) | 2016-09-21 | — | — | EP | claimed |
| WO-2016144979-A1 | DERMATOPHYTOSIS PROPHYLAXIS AND TREATMENT | THE CHILDREN'S MERCY HOSPITAL (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2015070226-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KUALITY HERBCEUTICS LLC (US) | 2015-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228672-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
| US-20200261529-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
| US-10918687-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
| US-20240050509-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
| US-20250213637-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
| US-20160279184-A1 | KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
| US-10624943-B2 | Kava derived therapeutic compounds and methods of use thereof | KLK5, KLK4, KLK2 | MAPT 4171/4885KMT2A 171/4885CYP3A4 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.